oncology polycythemia vera uncommon myeloproliferative neoplasm chronic leukemia bone marrow makes many red blood health concerns associated polycythemia vera caused blood thicker result increased red blood cells common elderly may symptomatic asymptomatic common signs symptoms include itching pruritus severe burning pain hands feet usually accompanied reddish bluish coloration skin patients polycythemia vera likely gouty arthritis treatment consists primarily phlebotomy well oral chemotherapy emerging treatments like longacting interferon formulations people polycythemia vera clinical symptoms polycythemia vera mostly due hyperviscosity blood classic symptom polycythemia vera pruritus itching particularly exposure warm water taking may due abnormal histamine prostaglandin itching present approximately patients polycythemia gouty arthritis may present peptic ulcer disease also common patients polycythemia vera likely due increased histamine mast cells may related increased susceptibility infection ulcercausing bacterium h classic symptom polycythemia vera related myeloproliferative disease essential thrombocythemia burning pain hands feet usually accompanied reddish bluish coloration skin erythromelalgia caused increased platelet count increased platelet stickiness aggregation resulting formation tiny blood clots vessels extremity responds rapidly treatment polycythemia vera pv primary polycythemia increase fraction volume occupied red cells blood caused neoplastic proliferation maturation erythroid megakaryocytic granulocytic elements produce referred panmyelosis contrast secondary polycythemias pv associated low serum level hormone erythropoietin epo instead pv cells often carry activating mutation tyrosine kinase gene acts signaling pathways eporeceptor making cells proliferate independent diagnostic criteria polycythemia vera modified world health organisation criteria polycythemia vera specifically outlined table emphasis given accurate histological observations proven predictors prognosis disease summarized verstovek following european hematology association major criteria pv diagnosis patients usually low level erythropoietin growth factor increases production red blood cells may considered minor diagnostic feature mutation kinase strongly associated polycythemia mutation patients exon mutations also people untreated polycythemia vera substantial risk buddchiari syndrome hepatic vein untreated polycythemia vera fatal median survival patients data effect lifespan individual treated polycythemia vera inconclusive due rarity disease studies show median survival rate controlled polycythemia vera ranges years however observations people diagnosed patients live close normal life frequent blood withdrawals phlebotomy one form treatment often may combined therapies removal blood body induces iron deficiency thereby decreasing hemoglobin hematocrit level reducing risk blood clots phlebotomy typically performed bring hematocrit red blood cell percentage men observed phlebotomy also reduces cognitive medications also used reduce number red blood cells include hydroxyurea interferon therapy among tendency practitioners avoid chemotherapy possible especially young patients result research indicating possible increased risk transformation acute myelogenous leukemia aml hydroxyurea considered safer chemotherapy aspect still debate longterm indications lung cancer drug erlotinib may additional treatment option certain genetic ruxolitinib brand name jakafi janus kinase inhibitor also used treat ropeginterferon besremi approved medical use european union february united states november ropeginterferon first medication approved us food drug administration fda treat polycythemia vera people take regardless treatment history first interferon therapy specifically approved polycythemia interferon also polycythemia vera occurs age although incidence increases age one study found median age diagnosis mayo clinic study olmsted county minnesota found highest incidence people aged overall incidence minnesota population per personyears disease common men cluster around toxic site confirmed northeast pennsylvania httpsenwikipediaorgwikierythremia